🕒 Tuesday 30 September 2025 Tue, 30 Sept 2025

Linius Technologies has released its audited FY2025 financial statements, revealing non-cash accounting adjustments related to Convertible Notes that increased reported losses and liabilities compared to prior unaudited figures.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Ryzon Materials has expanded its engineering contract with Xinhai to fast track production at its Nachu Graphite Project, alongside a $500,000 capital raising from Xinhai. The deal involves a $3.5 million contract largely settled through shares and options, pending shareholder approval.

Australia and New Zealand Banking Group Limited (ANZ) has announced a quarterly distribution of AUD 1.2556 per security on its capital notes, with a 70% franking rate and payment scheduled for December 22, 2025.

OzAurum Resources has launched a targeted drilling campaign at its Mulgabbie North Gold Project, aiming to expand high-grade zones and advance feasibility studies amid record gold prices.

Dalrymple Bay Infrastructure has appointed CEO Michael Riches as Managing Director, coinciding with the resignation of two non-executive directors following a significant shareholder sell-down.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Peak Rare Earths has officially been acquired by Shenghe Resources, with shareholders paid $0.443 per share and delisting from the ASX imminent. This marks a significant consolidation in the rare earths sector.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

Lakes Blue Energy has wrapped up drilling at its Wombat-5 well in Victoria’s Gippsland Basin, setting the stage for critical gas flow testing to assess commercial potential.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

VEEM Ltd has secured $14 million through a placement to fuel its expansion in defence manufacturing, including a landmark US$33 million licence agreement with Northrop Grumman. The company is poised to accelerate revenue in the second half of FY26 as it deepens ties with major US defence contractors.

VEEM Limited has completed a $14 million placement to accelerate its growth in the defence sector, highlighted by a new 9-year manufacturing licence agreement with Northrop Grumman valued initially at US$33 million. This positions VEEM alongside major US defence contractors and signals a significant step into the expanding submarine and naval supply chains.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

Spirit Technology Solutions forecasts strong FY26 growth with revenue surpassing $114 million and underlying EBITDA rising between 14% and 23%. The company signals ongoing expansion through organic and potential inorganic avenues.

Washington H. Soul Pattinson and Brickworks Limited have completed their long-anticipated merger, unveiling standalone FY25 results that highlight robust revenue growth and a significant profit turnaround. The combined entity, trading under the Soul Patts ticker SOL, is poised for diversified growth across property, building products, and investment portfolios.

Hillgrove Resources has secured $28 million through a two-tranche placement to accelerate copper production growth at its Kanmantoo mine, focusing on the Emily Star and Nugent projects.

Dotz Nano has secured its first commercial order for its innovative Amine-Modified Polymer CO2 sorbent from a leading automotive innovation hub, marking a key step toward commercial deployment in sustainable aviation fuel production.